260 related articles for article (PubMed ID: 32427023)
1. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
2. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
3. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
Allison K; Patel DG; Greene L
JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
[TBL] [Abstract][Full Text] [Related]
5. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
6. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
7. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
8. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.
Tahhan AS; Vaduganathan M; Greene SJ; Alrohaibani A; Raad M; Gafeer M; Mehran R; Fonarow GC; Douglas PS; Bhatt DL; Butler J
JAMA Cardiol; 2020 Jun; 5(6):714-722. PubMed ID: 32211813
[TBL] [Abstract][Full Text] [Related]
9. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs.
Scott PE; Unger EF; Jenkins MR; Southworth MR; McDowell TY; Geller RJ; Elahi M; Temple RJ; Woodcock J
J Am Coll Cardiol; 2018 May; 71(18):1960-1969. PubMed ID: 29724348
[TBL] [Abstract][Full Text] [Related]
10. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
[TBL] [Abstract][Full Text] [Related]
11. Disparities in reporting and representation by sex, race, and ethnicity in endovascular aortic device trials.
Marcaccio CL; O'Donnell TFX; Dansey KD; Patel PB; Hughes K; Lo RC; Zettervall SL; Schermerhorn ML
J Vasc Surg; 2022 Nov; 76(5):1244-1252.e2. PubMed ID: 35623599
[TBL] [Abstract][Full Text] [Related]
12. The impact of the globalization of cancer clinical trials on the enrollment of Black patients.
Tharakan S; Zhong X; Galsky MD
Cancer; 2021 Jul; 127(13):2294-2301. PubMed ID: 33682111
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of race/ethnicity in trials leading to anti-rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration.
Xie Y; Liu Y; Qin Y; Chen X; Xie Q
Int J Rheum Dis; 2023 Dec; 26(12):2489-2497. PubMed ID: 37854006
[TBL] [Abstract][Full Text] [Related]
14. Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs.
Fogacci F; Borghi C; Di Micoli A; Degli Esposti D; Cicero AFG
Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3305-3313. PubMed ID: 34656384
[TBL] [Abstract][Full Text] [Related]
15. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.
Idris MY; Fitzsimmons WE; Pemu P
Ther Innov Regul Sci; 2024 Jan; 58(1):175-183. PubMed ID: 37872439
[TBL] [Abstract][Full Text] [Related]
16. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications.
Liebowitz A; Spielman DB; Schlosser RJ; Stewart MG; Gudis DA
Laryngoscope; 2023 Apr; 133(4):755-763. PubMed ID: 35394648
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
18. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
19. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis.
Awan FA; Becker AB; Wang Y; Kimmelman J
Ann Intern Med; 2022 Dec; 175(12):1675-1684. PubMed ID: 36410007
[TBL] [Abstract][Full Text] [Related]
20. Minority Enrollment to Clinical Trials: Road to Increased Access.
Vose J
Oncology (Williston Park); 2021 Mar; 35(3):107. PubMed ID: 33818053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]